Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
12 4월 2022 - 9:30PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, announced the issuance of a key US Patent related to
its industry-leading minimal residual disease (MRD) and recurrence
platform, NeXT Personal.
The patent, US Patent No. 11,299,783, entitled “Methods and
Systems for Genetic Analysis,” was issued on April 12, 2022. The
‘783 patent claims novel methods for a partially personalized
assay, combining both tumor-informed and prespecified (tumor naïve)
content. Tumor-informed methods can provide high sensitivity for
detection of MRD. They can also support tracking of variants
specific to an individual patient’s cancer, such as those targeted
by specific therapies or which are thought to elicit an immune
response. Prespecified, tumor-naïve content can include variants
not detected on initial sequencing of a tumor, but which may emerge
and confer drug resistance as a tumor evolves. It can also include
driver mutations of a second primary tumor, which may arise
independently during the course of the initial cancer. The ‘783
patent is a member of a patent family that broadly describes
Personalis’ foundational work relating to the development of
personalized assays for disease identification and tracking.
Personalis’ recently introduced NeXT Personal platform leverages
many elements of the ‘783 patent. It is unique among MRD assays in
that it combines a highly sensitive measurement of tumor burden
with simultaneous tracking of thousands of tumor variants, both
tumor-informed and prespecified, in a single panel design.
The issuance of the ‘783 patent adds to Personalis’ growing
intellectual property portfolio that includes multiple early
families related to personalized genetic testing. Overall,
Personalis has 19 issued US and foreign patents, spanning 16
distinct families, relating to advanced genomic sequencing and
analysis solutions. In addition, the company has over 25 pending US
and foreign patent applications that relate to its existing
advanced cancer detection platforms and novel research areas,
including methods for interpreting genetic data generated by its
platforms.
“Cancer is very complex and dynamic,” said John West, CEO and
co-founder of Personalis. “Our NeXT Personal approach combines
detection, quantification, and detailed characterization of a
patient’s tumor in a single, integrated data stream. As the cost
and turnaround time of both DNA sequencing and DNA synthesis have
rapidly improved, sensitive and detailed monitoring over a
patient’s entire clinical trajectory has become affordable, and we
believe that it will become the new standard of care.”
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics,
enabling the next generation of precision cancer therapies and
diagnostics. The Personalis NeXT Platform® is designed to adapt to
the complex and evolving understanding of cancer, providing its
biopharmaceutical customers and clinicians with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single sample. To enable cancer sequencing,
Personalis' Clinical Laboratory was built with a focus on clinical
accuracy, quality, big data, scale, and efficiency. The laboratory
is GxP-aligned as well as Clinical Laboratory Improvement
Amendments of 1988-certified and College of American
Pathologists-accredited. For more information, visit the Personalis
website and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the NeXT or NeXT Personal platforms, Personalis’ business
opportunities, leadership, plans, beliefs or expectations, the
presumed validity or enforceability of the company’s patents, the
potential issuance of additional patents from the company’s pending
or future patent applications, or other future events. Such
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from any
anticipated results or expectations expressed or implied by such
statements. Factors that could materially affect actual results can
be found in Personalis’ filings with the U.S. Securities and
Exchange Commission, including Personalis’ most recent reports on
Forms 8-K, 10-K and 10-Q, the company’s registration statement on
Form S-3 filed on December 30, 2020, and the company’s prospectus
supplement filed on January 3, 2022, and include those listed under
the caption “Risk Factors.” Personalis disclaims any obligation to
update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220412005234/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Temple
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024